Secondary erythrocytosis following drugs used in rifampicin/multidrug-resistant tuberculosis: a retrospective cohort study.

Autor:	Tesfamariam S; Product Evaluation and Registration Unit, National Medicines and Food Administration, Asmara, Eritrea sirakino2015@gmail.com., Ghebrenegus AS; Hazhaz Zonal Referral Hospital, Asmara, Eritrea., Woldu H; The Center for Health Analytics for National and Global Equity (C.H.A.N.G.E), Columbia, Missouri, USA., Fisseha E; Eritrean Air-Force Military Hospital, Asmara, Eritrea.; Merhano National Referral MDR-TB Hospital, Asmara, Eritrea., Belai G; Merhano National Referral MDR-TB Hospital, Asmara, Eritrea., Russom M; Eritrean Pharmacovigilance Center, National Medicines and Food Administration, Asmara, Eritrea.; Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands.; European Programme for Pharmacovigilance and Pharmacoepidemiology, University of Bordeaux, Bordeaux, France.
Jazyk:	angličtina
Zdroj:	BMJ open respiratory research [BMJ Open Respir Res] 2021 Nov; Vol. 8 (1).
DOI:	10.1136/bmjresp-2021-001064
Abstrakt:	Background: Multidrug-resistant tuberculosis (MDR-TB) drugs have never been associated with erythrocytosis. In Eritrea, however, several cases of incident erythrocytosis had been observed in the MDR-TB hospital. This study was aimed at exploring the association between MDR-TB drugs and secondary erythrocytosis, characterising the cases, and identifying other possible risk factors. Methods: A retrospective cohort study was conducted in Merhano National Referral MDR-TB hospital. Data were extracted from physically available clinical cards and laboratory results collected longitudinally between 23 June 2011 and 17 January 2021. Initially, univariate descriptive statistics (frequency, mean (SD), median (IQR) and range) were used as appropriate. Then, χ 2 or Fisher χ 2 test, and bivariate and/or multivariate Cox proportional hazard model were used to identify the predictors of incident erythrocytosis. All statistical analyses were conducted using R, and a two-sided alpha 0.05 was used to determine the statistical significance. Results: A total of 257 patients' medical cards were screened, and 219 were eligible for further analysis. The median age of the patients was 38 years (range: 13-90 years) and 54.8% were males. During the follow-up time, 31 (14.2%) patients developed secondary erythrocytosis yielding an incidence rate of 7.8 cases per 1000 person-months. On average, the median time to onset of the event was found to be 5-months (range: 1-24 months). Males were more likely to develop the event than females (adjusted HR=7.13, 95% CI=1.66 to 30.53), and as body weight increases by 1 kg, the likelihood of developing secondary erythrocytosis was found to increase by 7% (adjusted HR=1.07, 95% CI=1.03 to 1.10). Moreover, all cases of secondary erythrocytosis were found to be possibly associated with the MDR-TB drugs. Conclusion: The authors hypothesised that the incident erythrocytosis is possibly be associated with MDR-TB drugs, and further studies are required to substantiate this finding. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu